Selective NNMT inhibitor substrate site-targeting mechanism with IC50 of 1.2 M in reference assay conditions Selectivity over related methyltransferases does not significantly affect other enzymes in the NAD salvage pathway at research concentrations Reduces intracellular 1-methylnicotinamide (1-MNA) formation in cell-based assay models Studied in adipocyte, liver, and skeletal muscle cell-based research models examining NNMT-dependent methylation pathway dynamics Referenced at Sigma-Aldrich (SML2832) and in peer-reviewed literature on NNMT enzyme biology Membrane-permeable quaternary quinolinium scaffold studied for intracellular NNMT target engagement in cell-based models Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background 5-Amino-1MQ was first characterized as a selective NNMT inhibitor in published research literature in 2018
Because the BPC-157 peptide operates through VEGFR2 and NO pathways that are mechanistically distinct from TB-500s actin-based signaling and GHK-Cus collagen synthesis mechanisms, the three compounds address complementary aspects of tissue repair without documented antagonism in animal studies
This may include staying hydrated, maintaining a balanced diet, and monitoring for any unusual reactions
It cannot be legally prescribed off-label, and the FDA has explicitly stated it cannot be used in compounding pharmacies under federal law
The World Anti-Doping Agency (WADA) maintains a Prohibited List, which is the global standard for substances banned in sport
doi: 10.1016/S0140-6736(21)01751-7
